Compare Dow Inc (DOW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs GeneDx Holdings Corp — how do they compare? Dow Inc trades at $28.84 (market cap $20.65B), while GeneDx Holdings Corp trades at $67.82 (market cap $2.02B). The key difference: Dow Inc is far larger — about 10.2× GeneDx Holdings Corp's market cap, and Dow Inc pays a 4.9% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and GeneDx Holdings Corp for 19 Days on average.
| DOW | WGS | |
|---|---|---|
Market Cap | $20.65B | $2.02B |
Volume | 14,126,943 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $167.51 |
52-Week Low | $20.65 | $34.51 |
Typical Hold Time | 82 Days | 19 Days |
Enterprise Value | $36.34B | $2.05B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company faces fundamental challenges with negative net income margin (-3.13%) and ROE (-7.86%) despite beating recent EPS estimates. Revenue declined from $56.9B in 2022 to $40.0B in 2025, though 2026 projections show modest recovery to $41.3B. Analyst consensus is mixed with 28% buy ratings but a $34.22 price target suggesting 23% upside potential from current levels.
DOW presents a high-risk opportunity with significant valuation disconnect. While technicals are bearish and profitability metrics weak, the stock trades at attractive valuation multiples (P/S: 0.5x, P/B: 1.3x) with dividend support. Key risks include ongoing margin pressure, declining operating cash flow trend, and rising debt-to-asset ratio approaching 30%. The investment case hinges on earnings recovery and operational turnaround execution.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
